Harmony Biosciences Holdings (HRMY) Cost of Revenue (2019 - 2026)

Harmony Biosciences Holdings has disclosed Cost of Revenue across 8 years of filings, most recently posting $44.5 million for Q1 2026.

• Cost of Revenue for Q1 2026 came in at $44.5 million, up 44.94% year-over-year; the trailing twelve-month figure through Mar 2026 was $132.0 million (up 33.44% YoY), and the FY2025 annual result was $119.5 million, up 7.75% from the prior year.
• Cost of Revenue came in at $44.5 million for Q1 2026 at Harmony Biosciences Holdings, up from -$10.3 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $59.6 million in Q3 2025 to a low of -$10.3 million in Q4 2025.
• The 5-year median for Cost of Revenue is $26.9 million (2022), against an average of $25.8 million.
• Across the five-year window, Cost of Revenue surged 313.04% in 2022 and tumbled 220.86% in 2025, its largest moves.
• Harmony Biosciences Holdings' Cost of Revenue stood at $26.9 million in 2022, then advanced by 0.0% to $26.9 million in 2023, then sank by 68.35% to $8.5 million in 2024, then sank by 220.86% to -$10.3 million in 2025, then jumped by 532.79% to $44.5 million in 2026.
• The last three Cost of Revenue figures came in at $44.5 million (Q1 2026), -$10.3 million (Q4 2025), and $59.6 million (Q3 2025), per Business Quant data.